This could be a key move for future growth.
Larimar submitted the module of a rolling biologics license application to the U.S. Food and Drug Administration for the ...
IntraBio Inc. today announced that results from its pivotal Phase III clinical trial evaluating levacetylleucine for the treatment of Ataxia-Telangiectasia (A-T) have been published in The Lancet ...
Discusses Phase III Program Design and Durable Cardiac Improvements in Friedreich's Ataxia June 29, 2026 2:00 PM ...
Design Therapeutics has its proprietary GeneTAC platform, which gives them a small-molecule way to target repeat-expansion ...
Published in the open-access journal Ferroptosis and Oxidative Stress, the review by Giovanni Cravin and Giorgio Cozza from ...
Webcast on Monday, June 29, 2026, at 7:45 am ET BALA CYNWYD, Pa., June 26, 2026 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc ...
Scientists have uncovered a surprising new genetic cause of a rare movement disorder after analyzing nearly 3,000 patients with conditions affecting coordination and muscle control. The team ...
As the military braces for another summer, new data reveals a concerning trend in the ongoing battle against heat illness.
A little-known, rarely described condition, pseudologia fantastica, could be more prevalent and influential than anyone ...
SUNRISE-FA 2 study parameters include LVMI primary endpoint, 6-month topline efficacy analysis, inclusion criteria focused on abnormal baseline ...
As of Tuesday, June 30, Design Therapeutics, Inc.’s DSGN share price has surged by 5.06%, which has investors questioning if ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results